Cargando…
Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations
Paroxysmal nocturnal hemoglobinuria (PNH) is a nonmalignant clonal disorder resulting from somatic mutation in the PIG-A gene leading to a deficiency of the membrane-anchoring molecule glycosylphosphatidylinositol. The lack of expression of two glycosylphosphatidylinositol-anchored proteins involved...
Autores principales: | Al-Ani, Fatimah, Chin-Yee, Ian, Lazo-Langner, Alejandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975135/ https://www.ncbi.nlm.nih.gov/pubmed/27536121 http://dx.doi.org/10.2147/TCRM.S96720 |
Ejemplares similares
-
The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009) -
Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report
por: Fassett, Michael J., et al.
Publicado: (2021) -
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?
por: Bellido, M., et al.
Publicado: (2012) -
Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation
por: Brodsky, Andrés, et al.
Publicado: (2012) -
Low-dose prednisolone in patients with paroxysmal nocturnal hemoglobinuria and inadequate response to eculizumab
por: Moon, Ji Young, et al.
Publicado: (2017)